Skip to main content

Table 2 Clinician-reported participant characteristics

From: Content validity and ePRO usability of the BPI-sf and “worst pain” item with pleural and peritoneal mesothelioma

Clinical characteristics

Overall N = 21a

Pleural N = 18

Peritoneal N = 4

Years since mesothelioma diagnosis

 Mean (SD)

1.2 (1.5)

1.1 (1.5)

1.4 (1.9)

 Range (Min, Max)

(0.1, 4.8)

(0.1, 4.8)

(0.2, 4.2)

Stage of mesothelioma, n (%)b

 Stage I/Stage II

3 (14.3%)

3 (16.7%)

0 (0%)

 Stage III/Stage IV

17 (80.9%)

14 (77.8%)

4 (100%)

RECIST criteria, n (%)d

 Partial response (PR)

4 (19.0%)

2 (11.1%)

2 (50.0%)

 Progressive disease (PD)

4 (19.0%)

4 (22.2%)

0 (0%)

 Stable disease (SD)

10 (47.6%)

9 (50.0%)

2 (50.0%)

ECOG performance status grade

 Grade 0: Fully active

8 (38.1%)

7 (38.9%)

2 (50.0%)

 Grade 1: Restricted, light work only

13 (61.9%)

11 (61.1%)

2 (50.0%)

Comorbiditiesc

 Asthma

3 (14.3%)

3 (16.7%)

1 (25.0%)

 Anxiety/depression

2 (9.5%)

1 (5.6%)

1 (25.0%)

 Arthritis

2 (9.5%)

2 (11.1%)

0 (0%)

 Other cancere

10 (47.6%)

9 (50.0%)

1 (25.0%)

 Diabetes

2 (9.5%)

2 (11.1%)

0 (0%)

 Hypertension (high blood pressure)

12 (57.1%)

12 (66.7%)

0 (0%)

 Chest pain/abdominal pain

3 (14.3%)

2 (11.1%)

1 (25.0%)

 Otherf

6 (28.6%)

5 (27.8%)

1 (25.0%)

 None

1 (4.8%)

1 (5.6%)

0 (0%)

Current medicationsb

 Chemotherapy or other cancer treatment

18 (85.7%)

16 (88.9%)

3 (75.0%)

 Nutritional support

9 (42.9%)

8 (44.4%)

1 (25.0%)

 Pain medications/corticosteroids

11 (52.4%)

9 (50.0%)

3 (75.0%)

 Otherg

4 (19.0%)

3 (16.7%)

1 (25.0%)

  1. aOne patient had pleural and peritoneal disease and is included in both disease-specific columns
  2. bOne pleural participant with “unknown” status
  3. cNot mutually exclusive
  4. dThree pleural participants with “unknown” RECIST criteria
  5. eAs a requirement for study eligibility the participants had to be currently disease-free from other invasive malignancy and recovered from any toxicity related to previous or current anticancer therapies for other cancer
  6. fFor pleural participants: one participant reported having “GERD, gastroparesis, hyperlipidemia”; one participant reported having “allergies, hyperparathyroidism, GERD”; one participant reported having “chronic kidney disease”; one participant reported Congestive heart failure/Heart disease; one participant reported “COPD.” The one peritoneal participant reported having “anemia”
  7. gOther = Correction of metabolic syndrome disorder (n = 3; 2 pleural, 1 peritoneal). Antibiotics (n = 1 pleural)